Literature DB >> 21301836

Challenges in the treatment of gastroesophageal junction cancer.

Theodore Liakakos.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21301836     DOI: 10.1007/s00268-011-0977-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  14 in total

1.  Complete genome sequencing and network modeling to overcome trastuzumab resistance.

Authors:  Dimitrios H Roukos
Journal:  Pharmacogenomics       Date:  2010-08       Impact factor: 2.533

2.  Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?

Authors:  Dimitrios H Roukos
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 3.  Systems medicine: a real approach for future personalized oncology?

Authors:  Dimitrios H Roukos
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

4.  Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology.

Authors:  Dimitrios H Roukos
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

5.  Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"?

Authors:  Dimitrios H Roukos; Dimosthenis Ziogas
Journal:  Ann Surg Oncol       Date:  2008-07-09       Impact factor: 5.344

6.  Genomics and challenges toward personalized breast cancer local control.

Authors:  Dimitrios H Roukos; Efstathios Lykoudis; Theodore Liakakos
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

7.  Isolated tumor cells in breast cancer.

Authors:  Dimitrios H Roukos
Journal:  N Engl J Med       Date:  2009-11-12       Impact factor: 91.245

8.  Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

Authors:  Dimitrios H Roukos; Andreas Tzakos; George Zografos
Journal:  Expert Rev Anticancer Ther       Date:  2009-10       Impact factor: 4.512

9.  From tumor size and HER2 status to systems oncology for very early breast cancer treatment.

Authors:  Dimitrios H Roukos; Dimosthenis Ziogas
Journal:  Expert Rev Anticancer Ther       Date:  2010-02       Impact factor: 4.512

10.  Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.

Authors:  John V Reynolds; Narayanasamy Ravi; Cian Muldoon; John O Larkin; Suzanne Rowley; Ken O'Byrne; Donal Hollywood; Dermot O'Toole
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.